hypothesis that AD is caused by toxicity of amyloid plaques, which are responsible for a spectrum of changes including the formation of NFTs. The vast majority of typical late onset AD lacked a clear series of risk factors for the accumulation of Aβ. Furthermore, the epidemiology of AD lesions demonstrated that NFTs are more closely linked to dementia than senile plaques [2] . There is apparently a large genetic component to AD that has not yet been deciphered. Thus, it has become clear that AD is a more complex disease with a number of dimensions like cancer, and the need for more extensive funding to clearly understand and define the amyloid hypothesis as well as explore alternatives that are still in the early stages needs to be emphasized. A number of alternative hypotheses have been promulgated that either qualified the amyloid hypothesis or even proposed fresh alternative theories. These include: the hypothesis that apolipoprotein E (ApoE), the best defined risk factor for AD, is the cause of the disease and other factors such as Aβ act on ApoE [4] ; failure in energy metabolism in the brain similar to diabetes (Type III diabetes) [19] ; metal (Cu, Zn) homeostasis [1] ; and the hypothesis that the disease arises from a more fundamental failure in metabolism of a large number of membrane proteins, including AβPP, that ultimately result in a multiple pathway failure due to accumulation of metabolic intermediate of multiple proteins [16] .
The most popular among these is the theory that transient soluble Aβ aggregates (ADDLs), which are intermediates in amyloid plaque formation are neurotoxic and senile plaque lesions simply represent the spent shells in AD [6, 11] . This theory limits the forms of Aβ that are responsible for neurodegeneration and explains the failure to see clear correlation between dysfunction or loss of neurons and the senile plaque lesion characteristic of AD. Definition of the toxic intermediate form of Aβ then becomes crucial for the prevention and treatment of AD. It is particularly important to develop methods to measure the levels of the active intermediate first in order to identify methods to prevent its formation. One approach was to purify the toxic Aβ intermediate and define its role by directly delivering to the brain and block it with specific antibodies. The efforts by Karen Ashe in identifying a key toxic dodecamer intermediate, Aβ*56, deserves special mention in this regard [3, 12] .
The most extensive and successful anti-amyloid therapy attempted to date is the vaccination trial by Elan Corporation [13, 20] . Unfortunately this trial had to be stopped due to treatment-induced encephalitis [17] . An important development associated with the trial was the development of an assay termed as the tissue amyloid plaque immunoreactivity (TAPIR) assay [8] . In this assay, the immune response in vaccinated patients was evaluated by using sections from either AD brain or transgenic mouse brain. The assay was used to demonstrate that the vaccination resulted in a strong immune reaction against the aggregated form of Aβ42 but not against AβPP or its C-terminal fragments. A follow up study showed that TAPIR reactivity correlated with improvement in cognition in the small subset of vaccinated subjects. However, although TAPIR response correlated well with Aβ42 ELISA response, the latter did not correlate well with improved cognition [9, 10] . These studies clearly suggested that there may be specific forms of Aβ that lead to cognitive decline but most Aβ is normally well tolerated.
These findings emphasize that the role of Aβ in AD pathogenesis is complex and that a simple failure of an Aβ-lowering clinical trial does not necessarily rule out the amyloid hypothesis. Instead, more research is required in understanding the mechanisms that link changes in AβPP metabolism with AD in addition to examining alternative hypotheses. The paper by Wang et al. [21] is among the first to take advantage of this interesting finding and make an antibody, 3.4A10, that shows the same TAPIR-like immunoreactivity. This will help considerably in assays to follow up on the numerous Aβ-lowering clinical trials that should be completed fairly soon. In addition, this antibody may prove to be particularly useful for immunotherapy as it targets the specific subset of epitopes associated with improved retention of cognition over time in AD patients. The disruption of amyloid plaque in general may lead to an increase in toxic soluble Aβ oligomers and may therefore be undesirable. In addition, the inert amyloid plaque deposits are extensive and may provide structural support to the collapsing tissue around it and thus its removal may lead to distortion of neuronal connections. Indeed, the Elan clinical trial was not only fraught with difficulties associated with inflammation, but also with data showing shrinkage of brain upon plaque removal and an increased worsening of cognitive performance in patients with successful plaque removal [5, 14] . It is particularly heartening to note that this study finds that treatment with the TAPIR-like antibody, 3.4A10, results in a reduction of plaques as well as Aβ*56. In addition, there is evidence of reduced adverse effects such as microhemorrhages in the brain upon treatment with the 3.4A10 when compared to vaccination. In addition the antibody treatment did not show signs of inflammatory changes, at least in the TG2576 mouse model. Clearly these are early preclinical studies that need to be developed more thoroughly for use in diagnosis as a biomarker, passive immune treatment or evaluation of therapeutic agents that lower Aβ. Nevertheless it represents an important step forward to ultimately treat this intractable disease.
